These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27100303)

  • 61. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
    Salaj P; Brabec P; Penka M; Pohlreichova V; Smejkal P; Cetkovsky P; Dusek L; Hedner U
    Haemophilia; 2009 May; 15(3):752-9. PubMed ID: 19432926
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
    Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
    Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Experience with recombinant factor VIIa in Australia and New Zealand.
    McPherson J; Teague L; Lloyd J; Jupe D; Rowell J; Ockelford P; Ekert H; Street A; Faase A; Hedner U
    Haemostasis; 1996; 26 Suppl 1():109-17. PubMed ID: 8904184
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The use of recombinant activated factor VII in patients with acquired haemophilia.
    Tiede A; Amano K; Ma A; Arkhammar P; El Fegoun SB; Rosholm A; Seremetis S; Baudo F
    Blood Rev; 2015 Jun; 29 Suppl 1():S19-25. PubMed ID: 26073365
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.
    Schneiderman J; Rubin E; Nugent DJ; Young G
    Haemophilia; 2007 May; 13(3):244-8. PubMed ID: 17498072
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
    Schneiderman J; Nugent DJ; Young G
    Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
    Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J
    Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
    Hedner U
    Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Factor VIIa in the treatment of haemophilia.
    Hedner U
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):307-17. PubMed ID: 2103315
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world.
    Sørensen B; Benson GM; Bladen M; Classey S; Keeling DM; McLaughlin P; Yee TT; Makris M
    Haemophilia; 2012 Jul; 18(4):598-606. PubMed ID: 22151135
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Treatment of psoas haematoma in a patient with haemophilia and inhibitors].
    Janić D; Dokmanović L; Krstovski N; Rodić P; Lazić J; Smoljanić Z
    Srp Arh Celok Lek; 2008 Sep; 136 Suppl 3():222-5. PubMed ID: 19562873
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
    Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
    Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    Hedner U
    Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.